Table 1 |
||||||
|
Clinical features associated with systemic sclerosis autoantibodies |
||||||
|
Antibodies |
||||||
|
|
||||||
|
ACA |
Th/To |
U1RNP |
U3RNP |
Topo |
Pol III |
|
|
|
||||||
|
Patient characteristics |
Female |
MCTD |
African American |
|||
|
Disease subtype |
Limited |
Limited |
Limited |
Diffuse |
Diffuse |
Diffuse |
|
Joint/skin involvement |
↓ Joint |
↓ Joint |
↑ Joint |
↑↑ Skin |
||
|
Muscle involvement |
↑ |
↑ |
||||
|
Calcinosis |
↑ |
|||||
|
Acroosteolysis |
↑ |
↑ |
||||
|
DUs |
Yes |
Yes |
||||
|
PAH ± PF |
PAH |
PAH |
PAH |
PAH + PF |
PF |
↓↓ PF |
|
Renal crisis |
Yes |
Yes |
↑ |
|||
|
|
||||||
|
ACA, anticentromere antibodies; DU, digital ulcer; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; PF, pulmonary fibrosis; Pol III, polymerase III; Topo, topoisomerase; U1RNP, U1 ribonuclear protein; U3RNP, U3 ribonuclear protein. |
||||||
|
Matucci-Cerinic et al. Arthritis Research & Therapy 2007 9(Suppl 2):S7 doi:10.1186/ar2191 |
||||||